Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors

Current Topics in Medicinal Chemistry

Volumn 8, Issue 3, 2008, Pages 247-267

  Vandevoorde, Séverine ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b National Institute for Radioelements   (Belgium)

Author keywords

2 arachidonoylglycerol; Anandamide; Endocannabinoids; Fatty acid amide hydrolase; Monoacylglycerol lipase

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONOYL DIAZOMETHYL KETONE; ARACHIDONOYL SEROTONIN; ARACHIDONOYLSULFONYL FLUORIDE; ARACHIDONYL TRIFLUOROMETHYL KETONE; CANNABINOID RECEPTOR; CARBAMIC ACID DERIVATIVE; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; HYDANTOIN DERIVATIVE; HYDROLASE INHIBITOR; IMIDAZOLINE DERIVATIVE; ISOPROPYL DODECYLFLUOROPHOSPHONATE; METHYLARACHIDONOYLFLUOROPHOSPHONATE; N ARACHIDONOYLGLYCINE; N ARACHIDONOYLISOLEUCINE; N OLEOYLETHANOLAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLEAMIDE; PALMIDROL; PALMITOYL 2 METHYL ETHANOLAMIDE; PALMITOYLISOPROPYLAMIDE; POLYUNSATURATED FATTY ACID; PYRIDINE DERIVATIVE; UNINDEXED DRUG; VIRODHAMINE; AMIDASE; FATTY-ACID AMIDE HYDROLASE; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HYDROLYSIS; MOLECULAR CLONING; NONHUMAN; REVIEW; ANIMAL; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; METABOLISM; STRUCTURE ACTIVITY RELATION;

AMIDOHYDROLASES; ANIMALS; ENDOCANNABINOIDS; ENZYME INHIBITORS; HUMANS; MONOACYLGLYCEROL LIPASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 40349114245     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608783498005     Document Type: Review

References (122)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonnet T. I. Structure of a cannabinoid receptor and functionnal expression of the cloned cDNA. Nature 1990, 346, 561-564.
2. Munro, S.; Thomas, K. L.; Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
3. Pertwee, R. G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 1997, 74, 129-180.
4. Brown, A. J.; Ueno, S.; Suen, K.; Dowell, S. J.; Wise, A. Molecular identification of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. 2005 symposium on the cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, page 16.
5. Koga, D.; Santa, T.; Fukushima, T.; Homma, H.; Imai, K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B. 1997, 690, 7-13.
6. Kondo, S.; Kondo, H.; Nakane, S.; Kodaka, T.; Tokumura, A.; Waku, K.; Sugiura, T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist: identification as one of the major species of monoacylglycerols in various rat tissues, and evidence for its generation through CA2+-dependent and -independent mechanisms. FEBS Lett. 1998, 429, 152-156.
7. Giuffrida, A.; Rodríguez de Fonseca, F.; Piomelli, D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 2000, 280, 87-93.
8. 1 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024.
9. Bisogno, T.; Melck, D.; Bodrov, M. Y.; Gretskaya, N. M.; Bezuglov, V. V.; De Petrocellis, L.; Di Matzo, V. N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 2000, 351, 817-827.
10. Huang, S. M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T. J.; Krey, J. F.; Chu, C. J.; Miller, J. D.; Davies, S. N.; Geppetti, P.; Walker, J. M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. USA 2002, 99, 8400-8405.
11. 1 cannabinoid receptors. Br. J. Pharmacol. 2004, 141, 253-262.
12. Fowler, C. J. Oleamide: a member of the endocannabinoid family? Br. J. Pharmacol. 2004, 141, 195-196.
13. Fride, E.; Mechoulam, R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol. 1993, 231, 313-314.
14. Smith, P. B.; Compton, D. R.; Welch, S. P.; Razdan, R. K.; Mechoulam, R.; Martin, B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 1994, 270, 219-227.
15. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394, 277-281.
16. Jaggar, S. I.; Hasnie, F. S,; Sellaturay, S.; Rice, A. S. C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76, 189-199.
17. 9-THC, WIN 55,212-2 and anandamide in mice. Neuroscience Lett. 1999, 263, 29-32.
18. Gauldie, S. D.; McQueen D. S.; Pertweé, R.; Chessell, I. P. Anandamide activates peripheral nociceptors in normal and arthritic knee joints. Br. J. Pharmacol. 2001, 132, 617-621.
19. Pertwee, R.; Griffin, G.; Hanus, L.; Mechoulam, R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 1994, 259, 115-120.
20. Varga, K.; Lake, K.; Martin, B. R.; Kunos, G. Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 1995, 278, 279-283.
21. Calignano, A.; Katona, I.; Desamaud, F.; Giuffrida, A.; La Rana, G.; Mackie, K.; Freund, T. F.; Piomelli, D. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000, 408, 96-101.
22. Melck, D.; De Petrocellis, L.; Orlando, P.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Marzo, V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000, 141, 118-126.
23. De Petrocellis, L.; Melck, D.; Palmisano, A.; Bisogno, T.; Laezza, C.; Bifulco, M.; Di Matzo, V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA 1998, 95, 8375-8380.
24. Sarker, K. P.; Obara, S.; Nakata, M.; Kitajima, I.; Maruyama, I. Anandamide induces apoptosis of PC-12 oells: involvement of superoxide and caspase-3. FEBS Lett. 2000, 472, 39-44.
25. Jacobsson, S. O.; Wallin, T.; Fowler, C. J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 2001, 299, 951-959.
26. Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, R. G.; Makriyannis, A.; Khanolkar, A.; Layward, L.; Fezza, F.; Bisogno, T.; Di Marzo, V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001, 15, 300-3002.
27. Panikashvili D.; Simeonidou, C.; Ben-Shabat, S.; Hanus, L.; Breuer, A.; Mechoulam, R.; Shohami, E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413, 527-531.
28. Ligresti, A.; Bisogno, T.; Matias, I.; De Petrocellis, L.; Cascio, M. G.; Consenza, V.; D'Argenio, G.; Scaglione, G; Bifulco, M.; Sorrentini, I.; Di Marzo, V. Possible endocannabinoid control of oolorectal cancer growth. Gastroenterology 2003, 125, 677-687.
29. De Marchi, N.; De Petrocellis, L.; Orlando, P.; Daniele, F.; Fezza, F.; Di Marzo, V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003, 2, 1-9.
30. Pagotto, U.; Marsicano, G.; Fezza, F.; Theodoropoulou, M.; Grubler, Y.; Stalla, J.; Arzberger, T.; Milone, A.; Losa, M.; Di Matzo, V.; Lutz, B.; Stalla, G. K. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J. Clin. Endocrinol, Metab. 2001, 76, 594-601.
31. Lastres-Becker, I.; Fezza, F.; Cebeira, M.; Bisogno, T.; Ramos, J. A.; Milone, A.; Fernandez-Ruiz, J.; Di Marzo, V. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Hungtington's disease. Neuroreport 2001, 12, 2125-2129.
32. Maccarrone, M.; Fride, E.; Bisogno, T.; Bari, M.; Cascio, M. G.; Battista, N.; Finazzi-Agro, A.; Suris, R.; Mechoulam, R.; Di Marzo, V. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol. Hum. Reprod. 2005, 11, 21-28.
33. Kirkham, T. C.; Williams, C. M.; Fezza, F.; Di Marzo, V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 2002, 136, 550-557.
34. Wagner, J. A.; Hu, K.; Bauersachs, J.; Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 2001, 38, 2048-2054.
35. Pertwee, R. G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005, 7, E625-E654.
36. Cravatt, B. F.; Giang, D. K.; Mayfield, S. P.; Boger, D. L.; Lerner, R. A.; Gilula, N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384, 83-87.
37. Giang, D. K.; Cravatt, B. F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. USA 1997, 94, 2238-2242.
38. Bracey, M. H.; Hanson, M. A.; Masuda, K. R.; Stevens, R. C.; Cravatt, B. F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002, 298, 1793-1796.
39. Dinh, T. P.; Carpenter, D., Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci USA 2002, 99, 10819-10824.
40. Ueda, N.; Yamanaka, K.; Yamamoto, S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 2001, 276, 35552-35557.
41. Tsuboi, K.; Hilligsmann, C.; Vandevoorde, S.; Lambert, D. M.; Ueda, N. N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolyzing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J. 2004, 379, 99-106.
42. Tsuboi, K.; Sun, Y. X.; Okamoto, Y.; Araki, N.; Tonai, T.; Ueda, N. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J. Biol. Chem. 2005, 280, 11082-11092.
43. Fowler, C. J.; Tiger, G. Cyclooxygenation of the arachidonoyl side chain of 1-arachidonoylglycerol and related compounds block their ability to prevent anandamide and 2-oleoylglycerol metabolism by rat brain in vitro. Biochem Pharmacol. 2005, 69, 1241-1245.
44. Kozak, K. R.; Prusakiewicz, J. J.; Marnett, L. J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 2004, 10, 659-667.
45. van der Stelt, M.; Noordermeer, M. A.; Kiss, T.; van Zadelhoff, G.; Merghart, B.; Veldink, G. A.; Vliegenthart, J. F. G. Eur. J. Biochem. 2000, 267, 2000-2007.
46. Kozak, K. R.; Gupta, R. A.; Moody, J. S.; Ji, C.; Boeglin, W. E.; DuBois, R. N.; Brash, A. R.; Marneft, L. J. 15-Lipoxygenase metabolism of 2-arachidonoylglycerol. J. Biol. Chem. 2002, 277, 23278-23286.
47. Hillard, C. L; Jarrahian, A. The movement of N-arachi-donoylethanolamine (anandamide) across cellular membranes. [i Chem. Phys. Loids 2000, 109, 123-134.
48. Hillard, C. J.; Jarrahian, A. Cellular accumulation of anandamide consensus and controversy. Br. J. Pharmacol. 2003, 140, 802-808.
49. Giuffrida, A.; Beltramo, M.; Piomelli, D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 2001, 298, 7-14.
50. Fowler, C. J.; Jacobsson, S. O. P. Cellular transport of anandamide, 2-arachidnoylglycerol and palmitoylethanolamide- targets for drug development? Prostaglandins Leukot. Essent. Fatty Acids 2002, 66, 193-200.
51. Glaser, S. T.; Kaczocha, M.; Deutsch, D. G. Anandamide transport: a critical review. Life Sci. 2005, 77, 1584-1604.
52. Dickason-Chesterfield, A. K.; Kidd, S. K.; Moore, S. A.; Schaus, J. M.; Liu, B.; Nomikos, G. G.; Felder, C. C. Pharmacological Characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell, Mol. Neurobiol. 2006, in press.
53. Vandevoorde, S.; Lambert, D. M. Focus on the three key enzymes hydrolyzing endocannabinoids as new drug targets. Curr. Pharm. Des. 2005, 11, 2647-2668.
54. Cravatt, B. F.; Demarest, K.; Patricelli, M. P.; Bracey, M. H.; Giang, D. K.; Martin, B. R.; lichtman, A. H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signalling in mice lacking fatty acid amide hydrolase. Proc. Natl Acad. Sci. USA 2001, 98, 9371-9376.
55. Deutsch, D. G.; Omeir, R.; Arreaza, G.; Salehani, D.; Prestwich, G. D.; Huang, Z.; Howlett, A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandaraide amidase. Biochem. Pharmacol. 1997, 53, 255-260.
56. De Petrocellis, L; Melck, D.; Ueda, N.; Maurelli, S.; Kurahaski, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel inhibitors of brain, neuional, and basophilic anandamide amidohydrolase. Biochem Biophys. Res. Commun. 1997, 231, 82-88.
57. Huang, Z:; 11u, S.; Street, I.; Laliberte, F.; Abdullah, K.; Desmarais, S.; Wang, Z.; Kennedy, B.; Payette, P.; Riendeau, D.; Weech, P.; Gresser, M. Methyl arachidonyl fluorophosphonate, a potent irreversible cPLA2 inhibitor, blocks the mobilization of arachidonic acid in human platelets and neutrophils. Mediators Inflamm. 1994, 3, 307-308.
58. Martin, B. R.; Beletskaya, I.; Patrick, G.; Jefferson, R.; Winckler, R.; Deutsch, D. G.; Di Marzo, V.; Dasse, O.; Mahadevan, A.; Razdan, R. K. Cannabinoid properties of methylfluorophosphonate analogs. J. Pharmacol. Exp. Ther. 2000, 294, 1209-1218.
59. Glaser, S. T.; Gatley, S. J.; Gifford; A. N. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. J. Phannacol. Exp. Ther. 2006, 316, 1088-1097.
60. Huang, Z.; Payette, P.; Abdullah, K; Cromlish, W. A.; Kennedy, B. P. Functional identification of the active site nucleophile of the human 85-kDa cytosolic phospholipase A2. Biochemistry 1996, 35, 3712-3721.
61. Edgemond, W. S.; Greenberg, M. J.; McGinley, P. J.; Muthian, S.; Campbell, W. B.; Hillard, C. J. Synthesis and characterization of diazomethylarachidonyl ketone: An irreversible inhibitor of Narachidonylethanolamine amidohydrolase. J. Pharmacol. Exp. Ther. 1998, 286, 184-190.
62. Segall, Y.; Quistad, G. B.; Nomura, D. K.; Casida, J. E. Arachidonylsulfonyl derivatives as cannabinoid CB1 receptor and fatty acid amide hydrolase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 3301-3303.
63. Koutek, B.; Prestwich, G. D.; Howlett, A. C.; Chin, S. A.; Salehani, D.; Akhavan, N.; Deutsch, D. G. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 1994, 269, 22937-22940.
64. Maureffi, S.; Bisogno, T.; De Petrocellis, L.; Di Luccia, A.; Marino, G.; Di Matzo, V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma « anandamide amidohydrolase ». FEBS Lett. 1995, 377, 82-86.
65. Bezuglov, V. V.; Manevich, Y.; Archakov, A. V.; Bobrov, M. Y.; Kuklev, D. V.; Petrukhina, G. N.; Makarov, V. A.; Buzaikov, G. A. Russian J. Bioorg. Chem. 1997, 23, 190-198.
66. Bisogno, T.; Melck, D.; De Petrocellis, L.; Bobrov, M. Y.; Gretskaya, N. M.; Bezuglov, V. V.; Sitachitta, N.; Gerwick, W. H.; Di Marzo, V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 1998, 248, 515-522.
67. Tzavara, E. T.; Moutsimilli, L.; Bisogno, T.; Di Marzo, V.; Phebus, L. A.; Nomikos, G. G.; Giros, B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 2006, 59, 508-515.
68. de Lago, E.; Petrosino, S.; Valenti, M.; Morera, E.; Ortega-Gutierrez, S.; Fernandez-Ruiz, J.; Di Marzo, V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol. 2005, 70, 446-452.
69. Bifulco, M.; Laezza, C.; Valenti, M.; Ligresti, A.; Portella, G.; Di Marzo, V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004, 18, 1606-1608.
70. Suplita II, R. L.; Gutierrez, T.; Fegley, D.; Piomelli, D.; Hohmann, A. G. Endocannabinoids at the spinal level regulate, but do not mediate, nonpioid stress-induced analgesia. Neuropharmacology 2006, 50, 372-379.
71. Boger, D. L.; Sato, H.; Lerner, A. E.; Hedrick, M. P.; Fecik, R. A.; Miyauchi, H.; Wilkie, G. D.; Austin, B. J.; Patricelli, M. P.; Cravatt, B. F. Exceptionnally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci USA 2000, 97, 5044-5049.
72. Huang, S. M.; Bisogno, T,; Petros, T. J.; Chang, S. Y.; Zavitsanos, P. A.; Zipldn, R. E.; Sivakumar, R.; Coop, A.; Maeda, D. Y.; De Petrocellis, L.; Burstein, S.; Di Marzo, V.; Walker, J. M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 2001, 276, 42639-42644.
73. Cascio, M. G.; Minassi, A.; Ugresti, A.; Appendino, G.; Burstein, S.; Di Marzo, V. A structure-activity relationship- study on N-arachidonoyl-amino acids as possible, endogenous inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 2004, 314, 192-196.
74. Patterson, J. E.; Othnann, I. R.; Cravatt, B. F.; Boger, D. L.; Wong, C. H.; Lerner, R. A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J. Am. Chem. Soc. 1996, 118, 5938-5945.
75. Boger, D. L.; Sato, H.; Lemer, A. E.; Austin, B. J.; Patterson, J. E.; Patricelli, M. P.; Cravatt, B. F. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg. Med. Chem. Lett. 1999, 9, 265-270.
76. Boger, D. L; Miyauchi, H.; Hedrick, M. P. α-keto heterocycle inhibitors of fatty acid amide hydrolase: Carbonyl group modification and α-substitution. Bioorg. Med. Chem. Lett. 2001, 11, 1517-1520.
77. Boger, D. L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R. A.; Cheng, H.; Hwang, I.; Hedrick, M. P.; Leung, D.; Acevedo, O.; Guimarães, C. R. W.; Jorgensen, W. L.; Cravatt, B. F. Discovery of a potent, selective, and efficacious class of reversible α-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem. 2005, 48, 1849-1856.
78. Leung, D.; Hardouin, C.; Boger, D. L.; Cravatt, B. F. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotecknol. 2003, 21, 687-691.
79. Leung, D.; Du, W.; Hardouin, C.; Cheng, H.; Hwang, I.; Cravatt, B. F.; Boger, D. L. Discovery of an exceptionnally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428.
80. Guimarães, C. R. W., Boger, D. L.; Jorgensen, W. L. Elucidation of fatty acid amide hydrolase inhibition by potent α-ketoheterocycle derivatives from Monte Carlo simulations. J. Am. Chem. Soc. 2005, 127, 17377-17384.
81. Vandevoorde, S.; Lambert, D. M.; Smart, D.; Jonsson, K. O.; Fowler, C. J. N-morpholino and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg. Med. Chem. 2003, 11, 817-825.
82. Vandevoorde, S.; Lavand'homme, P.; Fowler, C. J.; Tsuboi, K.; Ueda, N.; Rozenberg, R.; Habib Jiwan, J. L.; Lambert, D. M. 2004 symposium on the cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, page 15.
83. Jonsson, K. O.; Vandevoorde, S.; Lambert, D. M.; Tiger, G.; Fowler, C. J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 2001, 133, 1263-1275.
84. Vandevoorde, S.; Jonsson, K. O.; Fowler, C. J.; Lambert, D. M. Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J. Med. Chem. 2003, 46, 1440-1448.
85. Patricelli, M. P.; Lovato, M. A.; Cravatt, B. F. Chemical and mutagenic investigations of fatty acid amide hydrolase: Evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry 1999, 38, 9804-9812.
86. Patricelli, M. P.; Cravatt; B. F. Clarifying the catalytic roles of conserved residues in the amidase signature family. J. Biol. Chem. 2000, 275, 19177-19184.
87. McKinney, M. K.; Cravatt, B. F. Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J. Biol. Chem. 2003, 278, 37393-37399.
88. Tarzia, G.; Durand, A.; Tontini, A.; Piersanti, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Park, C.; Kathuria, S.; Piomelli, D. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J. Med. Chem. 2003, 46, 2352-2360.
89. Kathuria, S.; Gaetani, S.; Fegley, D.; Valiño, F.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; La Rana, G.; Calignano, A.; Giustino, A.; Tattoli, M.; Palmery, M.; Cuomo, V.; Piomelli, D. Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med. 2003, 9, 76-81.
90. Piomelli, D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G. Preparation and use of carbamates for modulation of anxiety through blockade of anandamide hydrolysis. PCT Int. Appl. 2004033422, 2004.
91. Jayamanne, A.; Greenwood, R.; Mitchell, V. A.; Aslan, S.; Piomelli, D.; Vaughan, C. W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 2006, 147; 281-288.
92. Mor, M.; Rivara, S.; Lodola, A.; Plazzi, P. V.; Tarzia, G.; Duranti, A.; Tontini, A.; Piersanti, G.; Kathuria, S.; Piomelli, D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 2004, 47, 4998-5008.
93. Alexander, J. P.; Cravatt, B. F. Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol. 2005, 12, 1179-1187.
94. Basso, E.; Duranti, A.; Mor, M.; Piomelli, D.; Tontini, A.; Tarzia, G.; Traldi, P. Tandem mass spectrometic data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J. Mass Spectrom. 2004, 39, 1450-1455.
95. Abouabdellah, A.; Burnier, P.; Hoomaert, C.; Jeunesse, J.; Puech, F. Piperidinyl- and piperazinyl-alkylcarbamates, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. PCT Int. Appl. 2004099176, 2004.
96. Sit, S. Y.; Xie, K. Preparation of bisarylimidazolyl fatty acid amidohydrolase inhibitors for treatment of pain. PCT Int. Appl. 2002087569, 2002.
97. Muccioli, G. G.; Fazio, N.; Scriba, G. K. E.; Poppitz, W.; Cannata, F.; Poupaert, J. H.; Wouters, J.; Lambert D. M. Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. J. Med. Chem. 2006, 49, 417-425.
98. Fowler, C. J.; Tiger, G.; Stenström, A. Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J. Pharmacol. Exp. Ther. 1997, 283, 729-734.
99. Fowler, C. J.; Janson, U.; Johnson, R. M.; Wahlström, G.; Stenström, A.; Norström, A.; Tiger, G. Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch. Biochem. Biophys. 1999, 362, 191-196.
100. Fowler, C. J.; Böjesson, M.; Tiger G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br. J. Pharmacol. 2000, 131, 498-504.
101. Holt, S.; Nilsson, J.; Omeir, R.; Tiger, G.; Fowler, C. J. Effects of pH on the inhibition of fatty acid amidohydrolase by ibuprofen. Br. J. Pharmacol. 2001, 133, 513-520 + Erratum in Br. J. Pharmacol. 2001, 134, 451.
102. Fowler, C. J.; Holt, S.; Tiger, G. Acidic nonsteroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J. Enzym. Inhib. Med. Chem. 2003, 18, 55-58.
103. Guindon, J.; De Léan, A.; Beaulieu, P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 2006, 121, 85-93.
104. Ates, M.; Hamza, M.; Seidel, K.; Kotalla, C. E.; Ledent, C.; Gühring, H. Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formialin test. Eur. J. Neurosci. 2003, 17, 597-604.
105. Seidel, K.; Hamza, M.; Ates, M.; Gühring, H. Flurbiprofen inhibits capsaicin induced calcitonin gene related peptide release from rat spinal cord via an endocannabinoid dependent mechanism. Neurosci. Lett. 2003, 338, 99-102.
106. Gühring, H.; Hamza, M.; Sergejeva, M.; Ates, M.; Kotalla, C. E.; Ledent, C.; Brune, K. A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur. J. Pharmacol. 2002, 454, 153-163.
107. Holt, S.; Paylor, B.; Boldrup, L.; Sundström, A.; Cocco, M. T.; Onnis, V.; Tiger, G.; Fowler, C. J. Inhibition of fatty acid amide hydrolase, a key endocannbinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur. J. Pharmacol. 2007, 565, 26-36.
108. Karlsson, M.; Contreras, J. A.; Hellman, U.; Tornqvist, H.; Holm, C. cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J. Biol. Chem. 1997, 272, 27218-27223.
109. Saario, S. M.; Savinainen, J. R.; Laitinen, J. T.; Jävinen, T.; Niemi, R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem. Pharmacol. 2004, 67, 1381-1387.
110. Stella N. Identification of a novel monoacylglycerol lipase (MGL). 2006, 16th Annual symposium on the cannabinoids, Burlington, Vermont, International Cannabinoid Research Society, page 20.
111. Ghafouri, N.; Tiger, G.; Razdan, R. K.; Mahadevan, A.; Pertwee, R. G.; Martin, & B. R.; Fowler, C. J. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br. J. Pharmacol. 2004, 143, 774-784.
112. Vandevoorde, S.; Saha, B.; Mahadevan, A.; Razdan, R. K.; Pertwee, R. G.; Martin, B. R.; Fowler, C. J. Biochem. Biophys. Res. Commun. 2005, 337, 104-109.
113. Saario, S. M.; Salo, O. M. H.; Nevalainen, T.; Poso, A.; Laitinen, J. T.; Järvinen, T.; Niemi, R. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerrol in rat cerebellar membranes. Chem. Biol. 2005, 12, 649-656.
114. Saario, S. M.; Poso, A.; Juvonen, R. O.; Järvinen, T.; Salo-Ahen, O. M. H. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J. Med. Chem. 2006, 49, 4650-4656.
115. Quistad, G. B.; Klintenberg, R.; Caboni, P.; Liang, S. N.; Casida, J. E. Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. Toxicol. Appl. Pharmacol. 2006, 211, 78-83.
116. 3H]dodecanesulfonyl fluoride. Synthetic Commun. 2003, 33, 2151-2159.
117. Wu, S. Y.; Casida, J. E. Stereospecific intramolecular cyclization for asymmetric synthesis of (Rp)- and (Sp)-enantiomers of 2-octyl-and 2-phenyl-4H-1,3,2-benzodioxaphosphorin 2-oxides. Phosphorus, Sulfur and Silicon and the Related Elements 1995, 102, 177-184.
118. Kim, Y. A.; Lee, H. S.; Park, Y. C.; Lee, Y. T. A convenient method for oxidation of organophsophorus pesticides in organic solvents. Environ. Res. 2000, 84, 303-309.
119. Hohmann, A. G.; Suplita, R. L.; Bolton, N. M.; Neely, M. H.; Fegley, D.; Krey, J. F.; Walker, J. M.; Holmes, P. V.; Crystal, J. D.; Duranti, A.; Tontini, A.; Mor, M.; Tarzia, G.; Piomelli, D. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005, 435, 1108-1112.
120. Makara, J. K.; Mor, M.; Fegley, D.; Szabó, S. I.; Kathuria, S.; Astarita, G.; Durand, A.; Tontini, A.; Tarzia, G.; Rivara, S.; Freund, T. F.; Piomelli, D. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nature Neurosci. 2005, 8, 1139-1141.
121. Garin, J.; Melendez, E.; Merchan, F. L.; Tejero, T.; Villarroya, E. Synthesis of 3-aryl-2,4-dioxo-1,2,3,4-tetrahydroquinazolines and 2-arylamino-4-oxo-4H-3,1-benzoxazines from methyl N-arylthiocarbamates. Synthesis 1983, 5, 406-408.
122. Saario, S. M.; Palomäki, V.; Lehtonen, M.; Nevalainen, T.; Järvinen, T.; Laitinen, J. T. URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem. Biol. 2006, 13, 811-814.